A 27-year-old Puerto Rican man presented to Yale-New Haven Hospital with a six-week history of left-sided headache, diplopia, and drooping of the left side of his face. Cerebrospinal fluid examination showed a lymphocytic pleocytosis and a CT scan of the brain revealed an unusual intrapontine mass lesion requiring systemic antifungal therapy. This case emphasizes many of the diagnostic and therapeutic considerations required for effective therapy of fungal disease in the central nervous system.
tial. Urinalysis was normal. Lumbar puncture revealed an opening pressure of 230 mm of water, protein of 34 mg/dl, glucose 65 mg/dl with a cell count of 80 nucleated cells (93 lymphocytes and 7 monocytes) and 9 red blood cells. An India ink preparation on the CSF was negative. Cytologic examination of the CSF revealed numerous mononuclear cells and Grade II astrocytes. Computerized axial tomography of the brain (CT scan) ( Fig. 1 ) revealed a pontine mass lesion after twice the usual dose of radiocontrast dye was injected. Culture of the CSF revealed Cryptococcus neoformans. The CSF cryptococcal antigen was positive at 1:16 dilution and the CSF cryptococcal antibody was negative (1:2 with the combined therapy study is that they used this low dose of amphotericin B alone for four weeks and then increased the dose of amphotericin B to higher levels every other day for the final two weeks of therapy. In contrast, the combination regimen included 5-fluorocytosine (150 mg/kg of body weight per day) and 0.3 mg/kg of body weight of amphotericin B daily for six weeks. The patients who could not tolerate the combination regimen were removed from the combination group and were then treated with amphotericin B alone at the higher dose. Those patients were not added to the "amphotericin alone" group. However, if they are added to this group, the difference between the two regimens is no longer statistically significant.
Specifically, 32 patients were entered into the amphotericin B treated group and five of these patients did not adhere to the protocol. Of 27 adherent amphotericin B treated patients, 11 (41 percent) were cured or improved. Of the five who did not adhere to the protocol, but who 'were treated with amphotericin B alone, four were cured or improved. Thus, 15 of 32 (47 percent) amphotericin B treated patients were cured or improved. In contrast, 34 patients were entered into the combination treatment protocol and ten did not adhere, of whom seven couldn't because of 5-fluorocytosine toxicity. This means that 20 percent of patients on combination treatment developed toxicity sufficient to require discontinuing the 5-fluorocytosine. Of the 24 adherent patients, 16 (67 percent) were cured or improved. Furthermore, seven of the ten non-adherent patients who were started on combination therapy but who were continued on amphotericin B treatment alone in increased doses were cured or improved. Therefore, if we examine all patients treated with amphotericin B essentially as the major antifungal agent, favorable responses were obtained in 22 of 39 (56 percent) as compared with 16 of 24 (67 percent) essentially treated with combination therapy (chi square = 0.29, p = >0.5). Thus, while the combination regimen has been tentatively accepted at most centers, I believe that the data presented in this study are not conclusive enough to justify the statement that combination therapy is the regimen of choice in cryptococcal meningitis. DR. JASON DAVID GAINES (Assistant Clinical Professor of Medicine): What about arguing that with the combination regimen we can get by with lower doses of amphotericin and spare the patient some nephrotoxicity? DR. ANDRIOLE: That is an excellent question, Dr. Gaines. We encountered significant renal and hematologic toxicity in the two patients we have treated with combination therapy and that was more impressive than the toxicity we observed in the 70 patients treated with amphotericin alone. One possible explanation for this apparent increased toxicity in patients on combination therapy may be related to the mechanism of action of the two drugs in the combination. The cryptococcal cell contains cytosine permease which allows 5-fluorocytosine to enter the fungal cell, whereas human cells were thought to be relatively resistant to penetration by 5-fluorocytosine. Once 5-fluorocytosine enters the cell it is deaminated by cytosine deaminase to 5-fluorouracil which is then converted to uridine monophosphate by uridine 5-monophosphate pyrophosphorylase. In fact, five patients have been reported who have detectable 5-fluorouracil levels in their serum while on the drug. These were patients undergoing simultaneous treatment with amphotericin.
Another problem with 5-fluorocytosine is the development of resistance to this agent. For example, one of the problems in treating Candida infections with 5-fluorocytosine is that resistance develops quite rapidly. The development of in vitro resistance can occur at several possible steps. If resistance develops at the level of cytosine permease then one can simply increase the dose to produce a therapeutic effect. However, if resistance is due to block at the 5-monophosphate pyrophosphorylase level, increasing the dose of the 5-fluorocytosine will not result in benefit. Unfortunately, the major mechanism of Candida resistance to 5-fluorocytosine is at the uridine 5-monophosphate pyrophosphorylase level. I think we are going to see higher levels of 5-fluorouracil and a higher incidence of hematologic toxicity when the combined regimen is used as opposed to amphotericin B alone. On careful review of the combination therapy study, I note that 30 percent of the patients who received combination therapy had side effects. I [6] . This study employed a ten-week regimen of amphotericin, which was given in a daily dose sufficient to provide peak serum levels at least twice those necessary for in vitro inhibition of the infecting fungus, and showed excellent results. However, I would caution against strict extrapolation to this patient because this study was conducted on a group of patients with a variety of different organisms and with various stages of disease. Furthermore, the concept behind this study was that lower doses, given for a longer period (ten weeks) might be as effective as higher doses given for a shorter period (six weeks). In the patients that we have treated anywhere from three weeks to six months of therapy (mean: seven weeks) was required to eradicate cryptococcal meningitis. Therefore, I think a shorter course regimen would be of potential benefit in a select group of patients. However, I would be reluctant to advocate its use in all patients with cryptococcal meningitis. We used the mouse inoculation technique as a means of following patients in the 1950s and 1960s prior to the availability of current serologic methods. I still believe the mouse inoculation method is a sensitive index of organism load in these patients. We found that small members of viable cryptococcal organisms would kill a mouse within two weeks after inoculation. Of course, if one could show an equivalent benefit from combination therapy as from longer courses of amphotericin alone, we will have made a major impact on therapy of this disease. This test was performed because of the observation that a high level of 5-fluorocytosine resistance by Cryptococcus neoformans is associated with antagonism between it and amphotericin in vitro [3] . We were also interested in this result to precisely quantitate the need for combination therapy in this particular patient. The patient is on 150 mg/kg/day of 5-fluorocytosine and is now receiving 0.5 mg/kg/day of amphotericin. The higher dose of amphotericin was employed because of the large mass lesion present in the pons, and because of the concerns expressed by Dr. Andriole, that the dose of amphotericin used in the comparative study was low. The plan for this patient is to continue the combination treatment regimen following the usual hematologic and renal parameters.The role of serial CT scans in terminating treatment is unclear. A recent review from UCLA [4] summarized their experience in treating patients with crytococcal CNS mass lesions. Three of the patients were successfully treated with medical regimens. The cephalic CT scan was useful in prompting a change in antifungal therapy when new lesions were discovered. In addition, successfully treated patients had gradual decrease in the size of their mass lesions on CT scan. Reported cases of cryptoccal intracerebral mass lesions number under 100. Therefore prospective therapeutic trials will be dif-ficult to conduct. As noninvasive diagnostic techniques achieve greater sensitivity perhaps greater numbers of cryptococcal intracerebral mass lesions with or without associated meningitis will be discovered. DR One can detect cryptococcal antigens in the absence of live organisms. We have often also seen patients with positive India ink preps whose CSF was injected into mice and did not cause a lethal effect. This would suggest that the organisms seen were not alive. We used two negative mouse inoculation tests to warrant the discontinuation of treatment. I think that's the reason why our duration of treatment was longer than that reported in other series. DR. COLEMAN: The patient was discharged after receiving a total of two grams of amphotericin B. The patient's neurological deficit did not improve. A follow-up CT scan two months after discharge was unchanged from that obtained at the time of initial diagnosis. Editors' comment: The discussants have framed some important questions regarding the treatment of cryptococcal lesions of the central nervous system. Dr. Andriole advises caution before advocating the use of 5-fluorocytosine in combination with amphotericin as opposed to amphotericin alone for this disease. Not only does he question efficacy but voices concern about potential toxicity. Should combination therapy prove effective and safe, he suggests its chief benefit may be to shorten the prolonged treatment schedule required for treatment of this disease.
